Scarica l'app Stockscreener
3.26
8.94%
-0.32
Dopo l'orario di chiusura:
3.27
0.01
+0.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.58
Aprire:
$3.59
Volume 24 ore:
747.54K
Relative Volume:
2.76
Capitalizzazione di mercato:
$107.31M
Reddito:
-
Utile/perdita netta:
$-12.48M
Rapporto P/E:
-8.359
EPS:
-0.39
Flusso di cassa netto:
$-7.93M
1 W Prestazione:
-37.55%
1M Prestazione:
-20.68%
6M Prestazione:
-2.40%
1 anno Prestazione:
+14.39%
Intervallo 1D:
$3.25
$3.5991
Intervallo di 1 settimana:
$3.25
$5.4566
Portata 52W:
$2.07
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Nome
Anixa Biosciences Inc
Settore
Industria
Telefono
408-708-9808
Indirizzo
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Confronta ANIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
3.26 | 117.84M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-21 | Iniziato | Maxim Group | Buy |
| 2022-12-23 | Iniziato | Chardan Capital Markets | Buy |
| 2021-04-12 | Iniziato | H.C. Wainwright | Buy |
Anixa Biosciences Inc Borsa (ANIX) Ultime notizie
ANIX: Breast cancer vaccine phase I showed 75% robust immune response and strong safety profile - TradingView — Track All Markets
Cleveland Clinic transfers breast cancer vaccine IND to Anixa - marketscreener.com
Anixa Biosciences (ANIX) Advances Breast Cancer Vaccine Developm - GuruFocus
Anixa Biosciences takes over breast cancer vaccine IND from Cleveland Clinic - Investing.com
Anixa Biosciences takes over breast cancer vaccine IND from Cleveland Clinic By Investing.com - Investing.com South Africa
Anixa Biosciences (NASDAQ: ANIX) assumes IND, plans Phase 2 cancer vaccine trial - Stock Titan
D. Boral Capital Maintains Anixa Biosciences (ANIX) Buy Recommendation - Nasdaq
Anixa Biosciences (ANIX) Shares Drop 21% After Phase 1 Vaccine D - GuruFocus
Anixa Biosciences falls on phase 1 data for breast cancer vaccine - Seeking Alpha
Anixa Biosciences (NASDAQ:ANIX) Given "Buy" Rating at D. Boral Capital - MarketBeat
ANIX: D. Boral Capital Maintains Buy Rating with $10 Price Targe - GuruFocus
Anixa Biosciences Reports Positive Phase 1 Trial Results - TipRanks
Anixa Biosciences Inc Announces Positive Phase 1 Data for Breast Cancer Vaccine - TradingView — Track All Markets
Anixa Biosciences Says Breast Cancer Vaccine Candidate Meets Key Endpoints in Phase 1 Trial - marketscreener.com
Anixa Biosciences Shares Jump Over 15% In After-Hours Trading — Here's Why - Benzinga
Anixa Biosciences (ANIX) Presents Promising Phase 1 Breast Cance - GuruFocus
Anixa’s breast cancer vaccine shows positive Phase 1 results - Investing.com
Anixa Biosciences (NASDAQ: ANIX) Phase 1 breast cancer vaccine data met endpoints with 74% immune response - Stock Titan
Cleveland Clinic Presents Final Results of Phase 1 Clinical Trial of Preventive Breast Cancer Vaccine Study - Cleveland Clinic Newsroom
Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 - PR Newswire
Anixa Biosciences (NASDAQ: ANIX) sets Dec. 15 talk on Phase 1 breast cancer vaccine - Stock Titan
Anixa Biosciences (NASDAQ: ANIX) unveils final Phase 1 breast cancer vaccine results at 2025 SABCS - Stock Titan
Will Anixa Biosciences Inc. (CY71) stock beat Nasdaq index returns2025 Risk Factors & Real-Time Stock Entry Alerts - Newser
Why Anixa Biosciences Inc. (CY71) stock is trending on social mediaPortfolio Update Report & Fast Momentum Stock Entry Tips - Newser
Will Anixa Biosciences Inc. stock see PE expansionWeekly Trading Summary & Risk Controlled Stock Pick Alerts - Newser
Is Anixa Biosciences Inc. stock undervalued vs historical averagesJuly 2025 WrapUp & Free Technical Pattern Based Buy Signals - Newser
Who are in the management team of Anixa Biosciences, Inc.? - Markets Mojo
Is Anixa Biosciences Inc. stock a bargain at current levelsJuly 2025 Opening Moves & Community Consensus Stock Picks - Newser
How risky is Anixa Biosciences Inc. (CY71) stock compared to peersLayoff News & Accurate Intraday Trading Signals - Newser
Can Anixa Biosciences Inc. (CY71) stock sustain double digit ROEJuly 2025 Action & Stepwise Trade Signal Implementation - Newser
How Anixa Biosciences Inc. stock compares to growth peersJuly 2025 Catalysts & Risk Adjusted Buy/Sell Alerts - Newser
Anixa Biosciences (ANIX) Stock Analysis Report | Financials & Insights - Benzinga
Why retail investors pile into Anixa Biosciences Inc. stock2025 Institutional Moves & High Accuracy Trade Alerts - moha.gov.vn
Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial (PR Newswire) - Aktiellt
Can Anixa Biosciences Inc. stock attract ESG capital inflows2025 Top Decliners & Low Risk High Win Rate Stock Picks - moha.gov.vn
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization - Quantisnow
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Zacks Research - MarketBeat
Is Anixa Biosciences Inc. stock a top momentum playGold Moves & Precise Entry and Exit Recommendations - newser.com
How geopolitical risks impact Anixa Biosciences Inc. (CY71) stockWeekly Trade Recap & High Return Trade Guides - newser.com
Why Anixa Biosciences Inc. stock is recommended by analysts2025 Risk Factors & Long-Term Growth Portfolio Plans - newser.com
Anixa Biosciences (ANIX) Price Target Increased by 11.11% to 10.20 - MSN
Intraday pattern recognizer results for Anixa Biosciences Inc.July 2025 EndofMonth & Reliable Price Breakout Alerts - newser.com
Anixa Biosciences Inc. stock prediction for this week2025 Bull vs Bear & Daily Volume Surge Signals - newser.com
Can Anixa Biosciences Inc. (CY71) stock resist broad market declinesPortfolio Value Summary & Real-Time Stock Entry Alerts - newser.com
Will Anixa Biosciences Inc. stock benefit from commodity pricesWeekly Trend Recap & Consistent Profit Alerts - newser.com
Anixa Biosciences Inc Azioni (ANIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anixa Biosciences Inc Azioni (ANIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | Director |
Jul 31 '25 |
Buy |
3.08 |
10,000 |
30,800 |
953,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 30 '25 |
Buy |
3.16 |
5,000 |
15,800 |
579,925 |
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
| KUMAR AMIT | Chief Executive Officer |
Jun 04 '25 |
Buy |
2.85 |
10,000 |
28,500 |
569,925 |
| Baskies Arnold M | Director |
Jan 28 '25 |
Buy |
2.82 |
5,000 |
14,100 |
120,000 |
| Titterton Lewis H jr | Director |
Jan 23 '25 |
Buy |
2.91 |
2,000 |
5,820 |
932,334 |
| Titterton Lewis H jr | Director |
Jan 24 '25 |
Buy |
3.00 |
1,000 |
3,000 |
933,334 |
| Titterton Lewis H jr | Director |
Jan 22 '25 |
Buy |
3.01 |
2,000 |
6,020 |
930,334 |
0.36%
1.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):